Protagonist Therapeutics Receives FDA Breakthrough Therapy Designation for Rusfertide in Polycythemia Vera

Author's Avatar
Jun 03, 2021

Designation further validates registrational path for rusfertide in polycythemia vera and facilitates potentially expedited development and review

PR Newswire